Paper Details

  1. Home
  2. Paper Details

Immune checkpoint inhibitor- and phosphatidylinositol-3-kinase inhibitor-related diabetes induced by antineoplastic drugs: two case reports and a literature review.

Author: GanLulu, GaoYue, LiLing, XiangCheng, YanYimin, ZhongMingyao

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

Immune checkpoint inhibitors (ICIs) and phosphatidylinositol-3-kinase inhibitors (PI3KIs) can cause diabetes as a side effect. This paper presents two case reports of diabetes induced by tremelimumab and apalutamide, respectively, and provides a comprehensive review of the literature on ICI- and PI3Ki-related diabetes.
Paper Details　
Original Abstract of the Article :
Immune checkpoint inhibitor (ICI)- and phosphatidylinositol-3-kinase inhibitor (PI3Ki)-related diabetes mellitus are common side effects of anti-tumor drug use that present mainly as hyperglycemia. Here, we present two case reports of diabetes mellitus caused by the use of tremelimumab and apalutami...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509015/

データ提供：米国国立医学図書館（NLM）

Diabetes: A Desert Storm for Cancer Patients

Imagine a patient battling a fierce desert storm, fighting a deadly disease while facing the added challenges of a serious side effect. That's the reality for some cancer patients who experience diabetes as a result of their treatment. This research investigates two specific forms of diabetes induced by anti-cancer drugs: those related to immune checkpoint inhibitors (ICIs) and phosphatidylinositol-3-kinase inhibitors (PI3KIs). The study explores the clinical features and treatment approaches for these forms of diabetes, providing valuable insights into this complex side effect.

ICI- and PI3Ki-Related Diabetes: A Shifting Desert Landscape

The study highlights the distinct characteristics and management approaches for ICI- and PI3Ki-related diabetes. It's like navigating a shifting desert landscape, where the terrain changes constantly. The study found that ICI-related diabetes often presents with diabetic ketoacidosis, a dangerous condition that requires immediate insulin treatment. In contrast, PI3Ki-related diabetes may be managed with oral medications like metformin and dapagliflozin. This research emphasizes the importance of early diagnosis and individualized treatment plans for these forms of diabetes.

Navigating the Desert of Diabetes: A Guide for Cancer Patients

This study provides valuable information for healthcare providers and cancer patients, helping them understand the different forms of diabetes induced by anti-cancer drugs. It's like finding a reliable guide in the desert of diabetes, providing insights into the potential risks and treatment options. This research encourages patients to discuss any changes in their blood sugar levels with their healthcare providers, ensuring early diagnosis and appropriate management.

Dr.Camel's Conclusion

This research sheds light on the challenges of managing diabetes in cancer patients, highlighting the unique features of ICI- and PI3Ki-related diabetes. It's a reminder that even in the face of a challenging diagnosis, there are ways to navigate the complex desert landscape of side effects and find effective treatment strategies.

Date :
  1. Date Completed 2023-09-26
  2. Date Revised 2023-09-26
Further Info :

Pubmed ID

37732122

DOI: Digital Object Identifier

PMC10509015

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.